tetano
Editor, Senior Moderator
Ann Clin Lab Sci
. 2022 Mar;52(2):332-335.
Comparison of ACCEL ELISA COVID-19 with Elecsys Anti-SARS-CoV-2 for Screening of COVID-19
Hanwool Cho[SUP] 1 [/SUP], Sung Jin Jo[SUP] 2 [/SUP], Eun-Jee Oh[SUP] 3 [/SUP], Hyunjung Kim[SUP] 4 [/SUP], Jehoon Lee[SUP] 2 [/SUP], Soo-Young Kim[SUP] 1 [/SUP], Hae Kyung Lee[SUP] 4 [/SUP], Hi Jeong Kwon[SUP] 5 [/SUP], Yeongsic Kim[SUP] 6 [/SUP]
Affiliations
Abstract
Objective: Although real-time reverse transcription-PCR (RT-PCR) is the gold standard for diagnosing coronavirus disease 2019 (COVID-19), simpler and faster antibody detection tests can be complementary for diagnosis of COVID-19. To manage the COVID-19 pandemic, the need for serologic testing has increased. In this report, the newly developed antibody detection assays ACCEL ELISA COVID-19 (ACCEL) and Elecsys anti-SARS-CoV-2 (Elecsys) were evaluated.
Methods: Serum samples submitted for routine laboratory testing were analyzed (66 and 161 PCR-positive and PCR-negative samples). After the samples were aliquoted, antibody detection tests were performed using ACCEL and Elecsys assays.
Results: When detection of viral RNA using RT-PCR was set as the reference method for diagnosis of COVID-19, the sensitivity was 83.3% and 75.8, and the specificity was 96.9 and 99.4% in ACCEL and Elecsys, respectively. The true positivity rates of ACCEL and Elecsys assays were 57.1%/42.9%, 57.1%/28.6%, 77.8%/66.7%, and 97.1%/97.1% among the specimens collected ≤3, 4-7, 8-14, and >14 days after symptom onset, respectively.
Conclusions: The ACCEL assay showed high sensitivity in samples collected within 7 days after symptom onset. Because many patients are asymptomatic in the early stage of SARS-CoV-2 infection, the ACCEL assay could be a good screening tool due to high sensitivity in the early stage of SARS-CoV-2 infection.
Keywords: ACCEL; COVID-19; Elecsys; SARS-CoV-2; anti-SARS-CoV-2 antibody; serological testing.
. 2022 Mar;52(2):332-335.
Comparison of ACCEL ELISA COVID-19 with Elecsys Anti-SARS-CoV-2 for Screening of COVID-19
Hanwool Cho[SUP] 1 [/SUP], Sung Jin Jo[SUP] 2 [/SUP], Eun-Jee Oh[SUP] 3 [/SUP], Hyunjung Kim[SUP] 4 [/SUP], Jehoon Lee[SUP] 2 [/SUP], Soo-Young Kim[SUP] 1 [/SUP], Hae Kyung Lee[SUP] 4 [/SUP], Hi Jeong Kwon[SUP] 5 [/SUP], Yeongsic Kim[SUP] 6 [/SUP]
Affiliations
- PMID: 35414512
Abstract
Objective: Although real-time reverse transcription-PCR (RT-PCR) is the gold standard for diagnosing coronavirus disease 2019 (COVID-19), simpler and faster antibody detection tests can be complementary for diagnosis of COVID-19. To manage the COVID-19 pandemic, the need for serologic testing has increased. In this report, the newly developed antibody detection assays ACCEL ELISA COVID-19 (ACCEL) and Elecsys anti-SARS-CoV-2 (Elecsys) were evaluated.
Methods: Serum samples submitted for routine laboratory testing were analyzed (66 and 161 PCR-positive and PCR-negative samples). After the samples were aliquoted, antibody detection tests were performed using ACCEL and Elecsys assays.
Results: When detection of viral RNA using RT-PCR was set as the reference method for diagnosis of COVID-19, the sensitivity was 83.3% and 75.8, and the specificity was 96.9 and 99.4% in ACCEL and Elecsys, respectively. The true positivity rates of ACCEL and Elecsys assays were 57.1%/42.9%, 57.1%/28.6%, 77.8%/66.7%, and 97.1%/97.1% among the specimens collected ≤3, 4-7, 8-14, and >14 days after symptom onset, respectively.
Conclusions: The ACCEL assay showed high sensitivity in samples collected within 7 days after symptom onset. Because many patients are asymptomatic in the early stage of SARS-CoV-2 infection, the ACCEL assay could be a good screening tool due to high sensitivity in the early stage of SARS-CoV-2 infection.
Keywords: ACCEL; COVID-19; Elecsys; SARS-CoV-2; anti-SARS-CoV-2 antibody; serological testing.